Skip to content

VWAV VWAV Increase Decrease In Deferred Offering Costs

Increase Decrease In Deferred Offering Costs at other companies

GTE
Gores Holdings X, Inc. Class A ordinary sharesGTEN
$184.67K
Oaktree Specialty Lending logo
Oaktree Specialty LendingOCSL
$33K
VenHub Global, Inc.
 logo
VenHub Global, Inc. VHUB
-$88.7K-500%
Altimmune logo
AltimmuneALT
$89K-28.8%
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO
$700K
Neuropace, Inc. logo
Neuropace, Inc.NPCE
$0-100%

Other financials

Income statement

See full
Revenue$10.0M
Operating income-$11.1M-7,634%
Net income-$12.9M-44,661%
EPS (diluted)-$0.66

Balance sheet

See full
Cash & equivalents$14.3M+23,310%
Total equity$98.6M+32,583%
Total assets$135.7M

Cash flow

See full
Operating cash flow-$3.4M-1,952%

Valuation

See full
Market cap$110.62M+226%

Returns & leverage

See full
Return on equity-52.8%
Current ratio0.4×

Where this comes from

Reported directly by VWAV in its filing.

Tagged under the XBRL concept VWAV:IncreaseDecreaseInDeferredOfferingCosts.

The official record: VWAV’s 10-K, filed December 31, 2025, on SEC EDGAR. View the filing →

Ask your AI about VWAV's increase decrease in deferred offering costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is VWAV's increase decrease in deferred offering costs?
VWAV (VWAV) reported increase decrease in deferred offering costs of $62.5K in Q3 2025.
What does increase decrease in deferred offering costs mean?
Tracks the net change in capitalized costs associated with the issuance of equity or debt securities, such as legal, accounting, and underwriting fees. These costs are typically amortized over the life of the security or offset against proceeds upon completion of the offering.